Thus, the experimental vaccine mRNA-1273 at the early stage of the clinical trials developed antibodies capable of neutralized SARS-CoV-2 coronavirus in the body of a human.
Moderna considers the vaccine to be safe and well-tolerated.
During the second phase of the trials, the researches will examine the influence of 50mg and 100 mg of the vaccine on the body. The third phase is planned for July 2020.
The company has started the clinical trials of the experimental vaccine against Covid-19 in March.
As we reported, the US biopharmaceutical company claims to have discovered an antibody that could shield the human body from the coronavirus and flush it out of a person’s system within four days. Sorrento Therapeutics will announce their discovery of the STI-1499 antibody, which the San Diego company said can provide "100% inhibition" of COVID-19, adding that a treatment could be available months before a vaccine hits the market.